Search research articles
Contact Us
Filters
Showing results (81-90 of 88) with videos related to
Page
of 9
Sort By:
You have reached the last page of results.
This site can display upto 88 results.
Plos Pathogens
|
March 2, 2021
Correction: RV144 HIV-1 vaccination impacts post-infection antibody responses
Thembi Mdluli, Ningbo Jian, Bonnie Slike, et al.
Science Translational Medicine
|
April 2, 2025
Ebola virus vaccination elicits Ebola virus-specific immune responses without substantial cross-reactivity to other filoviruses
Thembi Mdluli, Suzanne Wollen-Roberts, Mélanie Merbah, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 24, 2024
Safety and Immunogenicity of Accelerated Heterologous 2-Dose Ebola Vaccine Regimens in Adults With and Without HIV in Africa
Betty Mwesigwa, Fredrick Sawe, Janet Oyieko, et al.
The Journal of Infectious Diseases
|
April 19, 2018
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector
Lindsey R Baden, Stephen R Walsh, Michael S Seaman, et al.
The Lancet. HIV
|
April 20, 2019
Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial
Trevor A Crowell, Donn J Colby, Suteeraporn Pinyakorn, et al.
Plos Pathogens
|
August 1, 2017
Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection
Gustavo H Kijak, Eric Sanders-Buell, Agnes-Laurence Chenine, et al.
Plos Pathogens
|
September 15, 2017
Correction: Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection
Gustavo H Kijak, Eric Sanders-Buell, Agnes-Laurence Chenine, et al.
Iscience
|
February 8, 2021
Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates
Isabela Silva de Castro, Giacomo Gorini, Rosemarie Mason, et al.
Page
of 9
Search research articles
Search
Showing results (81-90 of 88) with videos related to
Sort By:
Page
of 9
You have reached the last page of results.
This site can display upto 88 results.
Plos Pathogens
|
March 2, 2021
Correction: RV144 HIV-1 vaccination impacts post-infection antibody responses
Thembi Mdluli, Ningbo Jian, Bonnie Slike, et al.
Science Translational Medicine
|
April 2, 2025
Ebola virus vaccination elicits Ebola virus-specific immune responses without substantial cross-reactivity to other filoviruses
Thembi Mdluli, Suzanne Wollen-Roberts, Mélanie Merbah, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 24, 2024
Safety and Immunogenicity of Accelerated Heterologous 2-Dose Ebola Vaccine Regimens in Adults With and Without HIV in Africa
Betty Mwesigwa, Fredrick Sawe, Janet Oyieko, et al.
The Journal of Infectious Diseases
|
April 19, 2018
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector
Lindsey R Baden, Stephen R Walsh, Michael S Seaman, et al.
The Lancet. HIV
|
April 20, 2019
Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial
Trevor A Crowell, Donn J Colby, Suteeraporn Pinyakorn, et al.
Plos Pathogens
|
August 1, 2017
Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection
Gustavo H Kijak, Eric Sanders-Buell, Agnes-Laurence Chenine, et al.
Plos Pathogens
|
September 15, 2017
Correction: Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection
Gustavo H Kijak, Eric Sanders-Buell, Agnes-Laurence Chenine, et al.
Iscience
|
February 8, 2021
Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates
Isabela Silva de Castro, Giacomo Gorini, Rosemarie Mason, et al.
Page
of 9